Tech Transfer eNews Blog

UVA invests in start-up developing novel therapeutic for arterial disease


By Jesse Schwartz
Published: August 7th, 2019

The University of Virginia Licensing and Ventures Group (UVA LVG) has invested in a start-up that is developing a novel therapeutic to treat Peripheral Arterial Disease (PAD).

Co-founded by UVA researcher Brian Annex, Merand Pharmaceuticals aims to commercialize the miR-93 therapeutic. UVA LVG has patented and licensed the technology to Merand, and the new investment from the UVA LVG Seed Fund & New Ventures, in collaboration with the Charlottesville Angel Network and other investors, will further advance the therapeutic towards Phase I clinical trials.

PAD is a common, progressive circulatory disease that affects over 200 million people worldwide. Patients suffering from PAD experience reduced blood flow to the legs caused by blockages in the arteries, leading to pain and chronic ulcers that often result in amputation.

The miR-39 therapeutic, which was developed in Annex’s lab at UVA, has been shown to promote the development of new blood vessels in order to restore blood flow in PAD patients.

“The standard care for patients with PAD has been stagnant since the 1990s, and Merand is well equipped with patented technology and an experienced leadership team to advance the treatment of this disease,” says Bob Creeden, managing director of the UVA LVG Seed Fund & New Ventures. “This investment aligns with our goal to further UVA discoveries toward commercial success.”

Source: LVG News

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment